HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Corbus Pharmaceuticals, maintaining a price target of $80. Analyst Andrew Fein continues to support the stock, indicating confidence in its potential.
September 23, 2024 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Corbus Pharmaceuticals, maintaining a price target of $80. Analyst Andrew Fein continues to support the stock, indicating confidence in its potential.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100